Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

This study is planned to prospectively evaluates the efficacy and safety of the zanubrutinib, obinutuzumab, and lenalidomide (ZGR) combination regimen in treatment-naïve follicular lymphoma (FL) patients in a Chinese population.

Trial Details

NCT ID
NCT07299149
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Induction Therapy: Zanubrutinib, obinutuzumab, lenalidomide
  • Maintenance therapy: Zanubrutinib, lenalidomide
Locations (sample)
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Gender: No restrictions; age ≥18 years.
  • Diagnosis: Histologically confirmed CD20-positive follicular lymphoma (FL), Grade 1, 2, or 3A, per 2016 WHO classification. All patients must provi…
  • Disease Stage \& Treatment Need:
  • Stage III or IV disease, or Stage II with bulky disease, meeting at least one of the following criteria:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →